Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

AGIO

Agios Pharmaceuticals Inc

Feb 17 • 04:00PM ET

27.82

-0.14 -0.50 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX GILD ALNY SRPT NBIX BLUE FOLD NVAX

| Held by: XBI VTI IWM VB VBK VXF IWN IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-7.12	Insider Own	5.61%	Shs Outstand	58.45M	Perf Week	3.27%
Market Cap	1.63B	Forward P/E	-	EPS next Y	-5.19	Insider Trans	-1.51%	Shs Float	55.31M	Perf Month	0.07%
Enterprise Value	815.83M	PEG	-	EPS next Q	-1.77	Inst Own	107.59%	Short Float	12.17%	Perf Quarter	-34.60%
Income	-412.78M	P/S	30.17	EPS this Y	8.70%	Inst Trans	0.76%	Short Ratio	4.01	Perf Half Y	-24.83%
Sales	54.03M	P/B	1.36	EPS next Y	20.09%	ROA	-27.89%	Short Interest	6.73M	Perf YTD	2.20%
Book/sh	20.41	P/C	1.91	EPS next 5Y	18.67%	ROE	-30.20%	52W High	46.00 -39.52%	Perf Year	-16.26%
Cash/sh	14.58	P/FCF	-	EPS past 3/5Y	-18.95% -8.46%	ROIC	-33.98%	52W Low	22.24 25.09%	Perf 3Y	0.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	55.97% -	Gross Margin	78.67%	Volatility	4.54% 4.37%	Perf 5Y	-47.01%
Dividend TTM	-	EV/Sales	15.10	EPS Y/Y TTM	-160.22%	Oper. Margin	-873.87%	ATR (14)	1.22	Perf 10Y	-33.65%
Dividend Ex-Date	-	Quick Ratio	11.06	Sales Y/Y TTM	48.03%	Profit Margin	-764.01%	RSI (14)	50.28	Recom	1.60
Dividend Gr. 3/5Y	- -	Current Ratio	11.46	EPS Q/Q	-9.68%	SMA20	0.36%	Beta	0.90	Target Price	38.12
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	86.09%	SMA50	1.57%	Rel Volume	0.38	Prev Close	27.96
Employees	540	LT Debt/Eq	0.02	Earnings	Feb 12 BMO	SMA200	-18.35%	Avg Volume	1.68M	Price	27.82
IPO	Jul 24, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.80% 65.14%	Trades		Volume	638,617	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Nov-20-25	Upgrade	Leerink Partners	Market Perform → Outperform	$34
Nov-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$28
Feb-24-25	Initiated	H.C. Wainwright	Buy	$58
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform	$51
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform	$60 → $56
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50

Show Previous Ratings

Feb-13-26 10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
Feb-12-26 02:02PM	Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:31PM	Agios Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
06:40AM	Agios Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Loading…
06:30AM	Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-05-26 10:00AM	Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-04-26 08:41AM	Williams to Report Q4 Earnings: What Surprise Awaits Investors? (Zacks)
Jan-26-26 07:00AM	Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET (GlobeNewswire)
Jan-19-26 05:19PM	Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory (Insider Monkey)
Jan-14-26 01:16PM	Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline (MarketBeat)
Jan-13-26 07:27AM	Agios Pharmaceuticals outlines 2026 strategic priorities (TipRanks)
Jan-12-26 07:00AM	Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth (GlobeNewswire)
Jan-05-26 07:00AM	Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (GlobeNewswire)
Dec-26-25 08:42AM	Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? (Zacks)
10:39AM	Loading…
Dec-25-25 10:39AM	Agios (AGIO) Gets 18.6% Boost from Aqvesme OK (Insider Monkey)
06:05AM	Agios Pharmaceuticals price target raised to $34 from $32 at BofA (TipRanks)
Dec-24-25 12:23PM	Here's Why Shares in Agios Pharmaceuticals Popped Today (Motley Fool) +18.63%
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
Dec-23-25 07:45PM	U.S. FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia (GlobeNewswire)
Dec-09-25 10:24AM	Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date (Zacks)
Dec-08-25 07:00AM	Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia (GlobeNewswire)
Nov-25-25 08:39AM	Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst (Insider Monkey) +7.30%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks) +9.98%
Nov-19-25 04:22PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) -50.89%
01:33PM	Why Shares in Agios Pharmaceuticals Got Crushed Today (Motley Fool)
11:30AM	A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%. (Barrons.com)
07:00AM	Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Nov-03-25 09:01AM	Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition (GlobeNewswire) -7.19%
Oct-31-25 01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
04:19PM	Loading…
Oct-30-25 04:19PM	Agios Pharmaceuticals Inc (AGIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:36AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-17-25 08:00AM	Agios' PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia (GlobeNewswire)
Oct-16-25 07:00AM	Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET (GlobeNewswire)
Sep-05-25 10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 07:00AM	Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia (GlobeNewswire) -11.03%
Sep-03-25 11:30AM	Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? (Zacks)
Aug-29-25 05:00AM	Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders (Insider Monkey)
Aug-04-25 04:01PM	Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia (GlobeNewswire)
09:46AM	Agios shares drop after report notes deaths of Pyrukynd patients (Investing.com)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
06:36AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-14-25 07:00AM	Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET (GlobeNewswire)
Jul-08-25 07:00AM	Agios Appoints Dr. Jay Backstrom to Board of Directors (GlobeNewswire)
Jun-17-25 01:37PM	Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat's Market Potential (Insider Monkey)
Jun-15-25 05:43AM	H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT (Insider Monkey)
Jun-09-25 08:40AM	Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders (Business Wire)
Jun-05-25 11:31AM	Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 11:30AM	Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
May-28-25 07:00AM	Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 (GlobeNewswire)
May-14-25 10:00AM	Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress (GlobeNewswire)
May-09-25 07:00AM	Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 (GlobeNewswire)
May-02-25 07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
07:00AM	Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 (GlobeNewswire)
03:02AM	Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-01-25 12:06PM	Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:50AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:47AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-24-25 10:02AM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-17-25 07:00AM	Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 (GlobeNewswire)
Apr-08-25 06:24AM	New Strong Sell Stocks for April 8th (Zacks) -5.29%
Apr-03-25 03:54AM	New Strong Sell Stocks for April 3rd (Zacks)
Mar-27-25 05:35AM	Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks)
Mar-26-25 09:39PM	Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-05-25 05:52PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer (GlobeNewswire)
Mar-04-25 07:00AM	Agios to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-01-25 09:20AM	Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-20-25 07:00AM	Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 (GlobeNewswire)
Feb-15-25 10:05AM	Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank (TipRanks)
Feb-14-25 02:09AM	Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Feb-13-25 12:45PM	Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years (Benzinga)
07:45AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:31AM	Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint (GlobeNewswire)
Feb-12-25 10:25AM	Agios Pharmaceuticals price target lowered to $54 from $55 at BofA (TipRanks)
08:05AM	Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-06-25 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 (GlobeNewswire)
Jan-13-25 04:29PM	Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential (Insider Monkey)
07:00AM	Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio (GlobeNewswire)
Jan-08-25 07:00AM	FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal)
07:00AM	Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 (GlobeNewswire)
Dec-18-24 07:00AM	European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease (GlobeNewswire) -7.01%
Dec-10-24 09:39AM	Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank (TipRanks) -5.39%
Dec-09-24 04:21PM	Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug (Investor's Business Daily) -21.09%
Dec-08-24 12:40PM	Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat (GlobeNewswire)
Dec-05-24 08:42AM	Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? (Zacks)
Nov-26-24 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-05-24 09:05AM	Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-01-24 03:03AM	Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Oct-31-24 07:45AM	Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates (Zacks)
06:42AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-23-24 07:00AM	Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Oct-17-24 07:00AM	Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)
Sep-27-24 10:34AM	Do Options Traders Know Something About Agios (AGIO) Stock We Don't? (Zacks) -5.08%

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Milanova Tsveta	Chief Commercial Officer	Jan 05 '26	Option Exercise	0.00	8,475	0	37,665	Jan 07 04:23 PM
Milanova Tsveta	Chief Commercial Officer	Jan 05 '26	Sale	27.02	2,872	77,601	34,793	Jan 07 04:23 PM
Milanova Tsveta	Officer	Jan 05 '26	Proposed Sale	27.22	2,872	78,176		Jan 05 04:05 PM
Burns James William	Chief Legal Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	34,650	Jan 02 08:18 PM
Burns James William	Chief Legal Officer	Dec 30 '25	Sale	27.09	2,932	79,428	31,718	Jan 02 08:18 PM
Goff Brian	Chief Executive Officer	Dec 30 '25	Option Exercise	0.00	38,278	0	149,333	Jan 02 08:16 PM
Goff Brian	Chief Executive Officer	Dec 30 '25	Sale	27.09	18,703	506,664	136,583	Jan 02 08:16 PM
Gheuens Sarah	Chief Medical Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	67,727	Jan 02 08:15 PM
Gheuens Sarah	Chief Medical Officer	Dec 30 '25	Sale	27.09	2,932	79,428	64,795	Jan 02 08:15 PM
Milanova Tsveta	Chief Commercial Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	32,122	Jan 02 08:15 PM
Milanova Tsveta	Chief Commercial Officer	Dec 30 '25	Sale	27.09	2,932	79,428	29,190	Jan 02 08:15 PM
Jones Cecilia	Chief Financial Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	40,326	Jan 02 08:14 PM
Jones Cecilia	Chief Financial Officer	Dec 30 '25	Sale	27.09	2,932	79,428	37,394	Jan 02 08:14 PM
Goff Brian	Officer	Dec 30 '25	Proposed Sale	27.16	18,703	507,973		Dec 30 04:20 PM
Gheuens Sarah	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:18 PM
Jones Cecilia	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:16 PM
Milanova Tsveta	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:13 PM
Burns James William	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:11 PM
Scadden David	Director	Nov 12 '25	Option Exercise	18.09	200	3,618	17,803	Nov 14 04:04 PM
Scadden David	Director	Nov 12 '25	Sale	43.84	200	8,768	17,603	Nov 14 04:04 PM
Gheuens Sarah	Chief Medical Officer	Nov 11 '25	Option Exercise	25.01	2,454	61,375	64,181	Nov 13 04:08 PM
Gheuens Sarah	Chief Medical Officer	Nov 11 '25	Sale	43.78	2,454	107,436	61,727	Nov 13 04:08 PM
SARAH GHEUENS	Officer	Nov 11 '25	Proposed Sale	43.78	2,454	107,441		Nov 12 10:35 AM
Gheuens Sarah	Chief Medical Officer	Oct 30 '25	Option Exercise	25.01	200	5,002	61,927	Nov 03 04:10 PM
Gheuens Sarah	Chief Medical Officer	Oct 30 '25	Sale	43.81	200	8,762	61,727	Nov 03 04:10 PM
SARAH GHEUENS	Officer	Oct 30 '25	Proposed Sale	43.81	200	8,762		Oct 30 05:02 PM
Gheuens Sarah	Chief Medical Officer	Oct 27 '25	Option Exercise	25.01	3,302	82,583	65,029	Oct 29 04:02 PM
Gheuens Sarah	Chief Medical Officer	Oct 27 '25	Sale	43.92	3,302	145,024	61,727	Oct 29 04:02 PM
SARAH GHEUENS	Officer	Oct 27 '25	Proposed Sale	43.92	3,302	145,028		Oct 27 04:32 PM
Scadden David	Director	Oct 08 '25	Option Exercise	18.09	200	3,618	17,803	Oct 10 04:18 PM
Scadden David	Director	Oct 08 '25	Sale	41.00	200	8,200	17,603	Oct 10 04:18 PM
DAVID SCADDEN	Director	Oct 08 '25	Proposed Sale	41.00	200	8,200		Oct 08 04:01 PM
Scadden David	Director	Sep 30 '25	Option Exercise	18.09	200	3,618	17,803	Oct 02 04:03 PM
Scadden David	Director	Sep 30 '25	Sale	40.00	200	8,000	17,603	Oct 02 04:03 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '25	Option Exercise	0.00	7,472	0	37,521	Sep 30 05:56 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '25	Sale	36.77	3,651	134,247	33,870	Sep 30 05:56 PM
DAVID SCADDEN	Director	Sep 30 '25	Proposed Sale	40.00	200	8,000		Sep 30 04:48 PM
Jones Cecilia	Officer	Sep 26 '25	Proposed Sale	36.77	3,651	134,247		Sep 26 04:15 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Sep 05 '25	Sale	36.87	8,546	315,091	868	Sep 09 04:26 PM
Scadden David	Director	Aug 27 '25	Option Exercise	18.09	200	3,618	17,803	Aug 29 04:09 PM
Scadden David	Director	Aug 27 '25	Sale	40.00	200	8,000	17,603	Aug 29 04:09 PM
DAVID T. SCADDEN	Director	Aug 27 '25	Proposed Sale	40.00	200	8,000		Aug 27 04:13 PM
Ballal Rahul D.	Director	Aug 11 '25	Option Exercise	0.00	2,302	0	12,414	Aug 13 04:55 PM
Smith Cynthia	Director	Aug 11 '25	Option Exercise	0.00	2,302	0	12,414	Aug 13 04:55 PM
Goff Brian	Chief Executive Officer	Aug 08 '25	Option Exercise	0.00	22,691	0	134,613	Aug 12 04:24 PM
Goff Brian	Chief Executive Officer	Aug 08 '25	Sale	36.67	11,085	406,487	123,528	Aug 12 04:24 PM
Goff Brian	Officer	Aug 08 '25	Proposed Sale	37.06	11,085	410,810		Aug 08 06:53 PM
Scadden David	Director	Jul 10 '25	Option Exercise	18.09	1,400	25,326	19,003	Jul 15 04:05 PM
Scadden David	Director	Jul 10 '25	Sale	40.00	1,400	56,000	17,603	Jul 15 04:05 PM
Gheuens Sarah	Chief Medical Officer	Jul 09 '25	Option Exercise	25.01	11,914	297,969	73,185	Jul 11 04:59 PM
Gheuens Sarah	Chief Medical Officer	Jul 09 '25	Sale	37.99	11,914	452,601	61,271	Jul 11 04:59 PM
DAVID SCADDEN	Director	Jul 10 '25	Proposed Sale	40.00	1,400	56,000		Jul 10 05:14 PM
SARAH GHEUENS	Officer	Jul 09 '25	Proposed Sale	37.99	11,914	452,632		Jul 09 04:59 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '25	Option Exercise	0.00	8,374	0	65,362	Jul 03 04:01 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '25	Sale	34.17	4,091	139,789	61,271	Jul 03 04:01 PM
Gheuens Sarah	Officer	Jul 01 '25	Proposed Sale	34.37	4,091	140,608		Jul 01 04:03 PM
Burns James William	Chief Legal Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	31,449	Jun 26 05:26 PM
Burns James William	Chief Legal Officer	Jun 24 '25	Sale	33.54	2,799	93,878	28,650	Jun 26 05:26 PM
Gheuens Sarah	Chief Medical Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	59,897	Jun 26 05:25 PM
Gheuens Sarah	Chief Medical Officer	Jun 24 '25	Sale	33.54	2,909	97,568	56,988	Jun 26 05:25 PM
Jones Cecilia	Chief Financial Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	31,829	Jun 26 05:24 PM
Jones Cecilia	Chief Financial Officer	Jun 24 '25	Sale	33.54	1,780	59,701	30,049	Jun 26 05:24 PM
Milanova Tsveta	Chief Commercial Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	28,892	Jun 26 05:23 PM
Milanova Tsveta	Chief Commercial Officer	Jun 24 '25	Sale	33.54	2,770	92,906	26,122	Jun 26 05:23 PM
Goff Brian	Chief Executive Officer	Jun 24 '25	Option Exercise	0.00	38,277	0	118,151	Jun 26 05:22 PM
Goff Brian	Chief Executive Officer	Jun 24 '25	Sale	33.54	18,700	627,198	105,401	Jun 26 05:22 PM
Goff Brian	Officer	Jun 24 '25	Proposed Sale	34.41	18,507	636,826		Jun 24 04:10 PM
Milanova Tsveta	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:08 PM
Jones Cecilia	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:07 PM
Gheuens Sarah	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:05 PM
Burns James William	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:01 PM
Ballal Rahul D.	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	10,112	Jun 23 04:27 PM
CAPELLO JEFFREY D	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	6,073	Jun 23 04:25 PM
Foster-Cheek Kaye I	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	7,468	Jun 23 04:24 PM
FOUSE JACQUALYN A	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	151,340	Jun 23 04:23 PM
Ho Maykin	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	17,032	Jun 23 04:21 PM
Owen Adams Catherine	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	6,073	Jun 23 04:20 PM
Scadden David	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	17,603	Jun 23 04:18 PM
Smith Cynthia	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	10,112	Jun 23 04:17 PM
CAPELLO JEFFREY D	Director	Jun 13 '25	Option Exercise	0.00	1,977	0	3,953	Jun 17 04:16 PM
Owen Adams Catherine	Director	Jun 13 '25	Option Exercise	0.00	1,977	0	3,953	Jun 17 04:15 PM
FOUSE JACQUALYN A	Director	Apr 08 '25	Option Exercise	0.00	15,933	0	156,717	Apr 10 04:02 PM
FOUSE JACQUALYN A	Director	Apr 10 '25	Sale	25.90	7,497	194,172	149,220	Apr 10 04:02 PM
FOUSE JACQUALYN A	Director	Apr 08 '25	Proposed Sale	25.90	7,497	194,172		Apr 08 05:58 PM
Burns James William	Chief Legal Officer	Mar 01 '25	Option Exercise	0.00	13,500	0	27,130	Mar 04 04:17 PM
Burns James William	Chief Legal Officer	Mar 03 '25	Sale	35.54	4,005	142,338	18,650	Mar 04 04:17 PM
Jones Cecilia	Chief Financial Officer	Mar 01 '25	Option Exercise	0.00	7,667	0	27,510	Mar 04 04:15 PM
Jones Cecilia	Chief Financial Officer	Mar 03 '25	Sale	35.54	2,275	80,854	21,843	Mar 04 04:15 PM
Milanova Tsveta	Chief Commercial Officer	Mar 01 '25	Option Exercise	0.00	5,667	0	24,573	Mar 04 04:12 PM
Milanova Tsveta	Chief Commercial Officer	Mar 03 '25	Sale	35.54	1,681	59,743	22,892	Mar 04 04:12 PM
Goff Brian	Chief Executive Officer	Mar 01 '25	Option Exercise	0.00	26,500	0	101,139	Mar 04 04:10 PM
Goff Brian	Chief Executive Officer	Mar 03 '25	Sale	35.54	12,947	460,136	83,139	Mar 04 04:10 PM
Gheuens Sarah	Chief Medical Officer	Mar 01 '25	Option Exercise	0.00	13,500	0	55,578	Mar 04 04:08 PM
Gheuens Sarah	Chief Medical Officer	Mar 03 '25	Sale	35.54	4,005	142,338	47,098	Mar 04 04:08 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01 '25	Option Exercise	0.00	5,577	0	10,141	Mar 04 04:06 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 03 '25	Sale	35.54	1,655	58,819	6,038	Mar 04 04:06 PM
Milanova Tsveta	Officer	Mar 03 '25	Proposed Sale	35.54	1,681	59,743		Mar 03 04:50 PM
Jones Cecilia	Officer	Mar 03 '25	Proposed Sale	35.54	2,275	80,854		Mar 03 04:49 PM
Goff Brian	Officer	Mar 03 '25	Proposed Sale	35.54	12,947	460,136		Mar 03 04:46 PM
Gheuens Sarah	Officer	Mar 03 '25	Proposed Sale	35.54	4,005	142,338		Mar 03 04:44 PM

Open in Screener

MNKD

Mannkind Corp

Feb 17 • 04:00PM ET

5.54

-0.12 -2.12 %

Healthcare • Biotechnology • USA • NASD

Peers: NVO LLY SNY PFE GNFT TNDM DIOD DNLI ABT VRTX

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO PBE DFAS

Index	RUT	P/E	58.75	EPS (ttm)	0.09	Insider Own	2.82%	Shs Outstand	307.03M	Perf Week	-6.26%
Market Cap	1.70B	Forward P/E	64.80	EPS next Y	0.09	Insider Trans	-5.21%	Shs Float	298.42M	Perf Month	-0.72%
Enterprise Value	1.67B	PEG	1.95	EPS next Q	0.02	Inst Own	57.53%	Short Float	8.79%	Perf Quarter	9.27%
Income	29.23M	P/S	5.42	EPS this Y	71.34%	Inst Trans	1.51%	Short Ratio	7.57	Perf Half Y	48.53%
Sales	313.79M	P/B	-	EPS next Y	-50.11%	ROA	6.10%	Short Interest	26.24M	Perf YTD	-2.29%
Book/sh	-0.15	P/C	6.54	EPS next 5Y	33.26%	ROE	-	52W High	6.51 -14.90%	Perf Year	2.21%
Cash/sh	0.85	P/FCF	39.80	EPS past 3/5Y	- -	ROIC	22.07%	52W Low	3.38 63.85%	Perf 3Y	-1.60%
Dividend Est.	-	EV/EBITDA	19.18	Sales past 3/5Y	55.84% 35.27%	Gross Margin	75.18%	Volatility	3.69% 5.60%	Perf 5Y	0.64%
Dividend TTM	-	EV/Sales	5.31	EPS Y/Y TTM	24.15%	Oper. Margin	24.32%	ATR (14)	0.27	Perf 10Y	10.80%
Dividend Ex-Date	-	Quick Ratio	3.04	Sales Y/Y TTM	17.44%	Profit Margin	9.32%	RSI (14)	45.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.29	EPS Q/Q	-36.95%	SMA20	-3.27%	Beta	0.76	Target Price	9.61
Payout	0.00%	Debt/Eq	-	Sales Q/Q	17.20%	SMA50	-3.71%	Rel Volume	0.54	Prev Close	5.66
Employees	407	LT Debt/Eq	-	Earnings	Nov 05 BMO	SMA200	12.58%	Avg Volume	3.46M	Price	5.54
IPO	Jul 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	59.57% 2.35%	Trades		Volume	1,885,253	Change	-2.12%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Nov-13-25	Initiated	Leerink Partners	Outperform	$7
Oct-20-25	Initiated	Wells Fargo	Overweight	$10
Oct-10-25	Initiated	Leerink Partners	Outperform	$9
Jul-16-25	Resumed	H.C. Wainwright	Buy	$9
Apr-10-25	Initiated	Mizuho	Outperform	$12
Feb-10-25	Initiated	Wedbush	Outperform	$11
Dec-20-24	Initiated	Wells Fargo	Overweight	$9
Dec-19-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $10
Sep-09-24	Resumed	Leerink Partners	Outperform	$7 → $8
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-10-23	Initiated	Wedbush	Outperform	$10
May-14-21	Initiated	RBC Capital Mkts	Sector Perform	$5
Dec-24-19	Initiated	Oppenheimer	Outperform	$2.50
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight	$3
May-14-19	Initiated	BTIG Research	Buy	$3
Mar-04-19	Initiated	SVB Leerink	Outperform	$3
Feb-22-19	Initiated	SVB Leerink	Outperform	$3
Feb-28-18	Downgrade	Maxim Group	Hold → Sell	$1
Nov-01-17	Downgrade	Maxim Group	Buy → Hold

Show Previous Ratings

Feb-13-26 12:01AM	Top Picks 2026- MannKind Corp. MNKD (MoneyShow)
Feb-09-26 06:05AM	MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) (GlobeNewswire)
Jan-29-26 01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire)
Jan-26-26 10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
06:05AM	MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy (GlobeNewswire)
11:55AM	Loading…
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 10:06AM	Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer (Zacks)
08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
08:02AM	MannKind Corporation (MNKD) Reveals 2026 Growth Drivers (Insider Monkey)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks) -6.63%
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
Jan-14-26 10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
Jan-13-26 12:00PM	MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
10:39AM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
03:57PM	Loading…
Jan-12-26 03:57PM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
Jan-08-26 08:05AM	MannKind Provides Business Updates and 2026 Growth Drivers (GlobeNewswire)
Jan-01-26 06:29AM	MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care (Insider Monkey)
Dec-23-25 08:05AM	MannKind Shares FUROSCIX Business Updates (GlobeNewswire)
Dec-01-25 08:05AM	MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease (GlobeNewswire)
Nov-11-25 04:05PM	MannKind to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
Nov-10-25 08:00AM	MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease (GlobeNewswire)
Nov-08-25 12:00PM	MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ... (GuruFocus.com)
Nov-06-25 09:00AM	MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes (GlobeNewswire) -5.94%
Nov-05-25 09:30AM	MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +10.58%
09:15AM	MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates (Zacks)
08:08AM	MannKind: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 07:56AM	MannKind Corp (MNKD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-30-25 10:00AM	Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
04:05PM	Loading…
Oct-29-25 04:05PM	MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025 (GlobeNewswire)
Oct-13-25 08:05AM	MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes (GlobeNewswire)
Oct-07-25 09:00AM	MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care (GlobeNewswire)
Sep-29-25 06:05AM	MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? (Zacks)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +25.05%
Aug-31-25 12:16AM	H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD) (Insider Monkey)
Aug-29-25 09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
05:10AM	MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza (Insider Monkey)
Aug-27-25 04:05PM	MannKind to Present at Upcoming Investor Conferences (GlobeNewswire) +11.06%
08:05AM	MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy (GlobeNewswire)
04:46AM	New Strong Sell Stocks for August 27th (Zacks)
Aug-25-25 11:56PM	Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7 (Insider Monkey) -5.11%
07:30AM	MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases (GlobeNewswire)
Aug-22-25 11:45PM	Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT (Insider Monkey)
Aug-17-25 06:26PM	MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline (Insider Monkey)
Aug-06-25 09:30AM	MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -13.16%
08:25AM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
07:10AM	MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement (GlobeNewswire)
07:05AM	MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update (GlobeNewswire)
Aug-05-25 09:56AM	MannKind Corp (MNKD) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-04-25 10:01AM	Wedbush Maintains a Buy on MannKind Corporation (MNKD) (Insider Monkey)
Aug-01-25 06:46AM	H.C. Wainwright Affirms MannKind Corp (MNKD)'s 'Buy' Rating Buoyed by Product Pipeline (Insider Monkey)
Jul-31-25 10:00AM	AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-30-25 04:05PM	MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025 (GlobeNewswire)
10:00AM	Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-28-25 02:27AM	RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating (Insider Monkey)
Jul-23-25 11:25AM	MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association (Insider Monkey)
Jul-17-25 11:11AM	Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer (GlobeNewswire)
Jul-11-25 11:28AM	Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT (Insider Monkey)
Jul-07-25 09:10AM	Wedbush Remains Bullish on MannKind Corporation (MNKD) (Insider Monkey)
Jun-25-25 09:28AM	Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 03:52PM	Leerink Partners Slashes MannKind Corporation's (MNKD) Price Target to $7, Keeps a Buy Rating (Insider Monkey) +5.14%
Jun-23-25 12:16PM	MannKind (MNKD) Presents Pediatric Insulin Trial Data (Insider Monkey)
Jun-09-25 04:05PM	MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23 (GlobeNewswire) -10.30%
May-27-25 09:15AM	INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29 (GlobeNewswire)
May-13-25 04:05PM	MannKind to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-25 10:31AM	MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-08-25 09:25AM	MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates (Zacks)
08:21AM	MannKind: Q1 Earnings Snapshot (Associated Press Finance)
08:05AM	MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 12:32PM	MannKind Q1 2025 Earnings Preview (Seeking Alpha)
10:12AM	MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
May-01-25 04:05PM	MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 (GlobeNewswire)
Apr-18-25 10:00AM	Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2) (Insider Monkey)
Apr-16-25 11:17AM	Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-07-25 12:30PM	MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options (GlobeNewswire)
Mar-10-25 06:05AM	MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza at the ATTD Conference, March 19-22 (GlobeNewswire)
Feb-27-25 02:19AM	MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
12:30AM	MannKind (MNKD) Q4 2024 Earnings Call Transcript (Motley Fool)
Feb-26-25 07:30PM	Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics (Zacks)
06:15PM	MannKind (MNKD) Q4 Earnings Meet Estimates (Zacks)
05:08PM	MannKind: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 10:30AM	MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-24-25 09:16AM	Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-19-25 04:05PM	MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 (GlobeNewswire)
Feb-06-25 04:05PM	MannKind to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-06-25 04:30PM	MannKind Expands Executive Leadership Team (GlobeNewswire)
08:47AM	Heres Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey)
Dec-18-24 07:00AM	MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash (GlobeNewswire)
Dec-16-24 06:05AM	MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza) (GlobeNewswire)
Dec-11-24 06:00AM	CDSCO Approves Afrezza (insulin human) Inhalation Powder in India (GlobeNewswire)
Nov-08-24 01:26PM	Q3 2024 MannKind Corp Earnings Call (Thomson Reuters StreetEvents)
02:28AM	MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-07-24 11:15PM	MannKind (MNKD) Q3 2024 Earnings Call Transcript (Motley Fool)
07:00PM	MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:40PM	MannKind (MNKD) Matches Q3 Earnings Estimates (Zacks)
04:34PM	MannKind: Q3 Earnings Snapshot (Associated Press Finance)

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tross Stuart A	Chief People & Workpl Officer	Jan 08 '26	Sale	6.33	47,006	297,548	985,007	Jan 09 08:30 PM
STUART A TROSS	Officer	Jan 08 '26	Proposed Sale	6.33	47,000	297,510		Jan 08 04:07 PM
Castagna Michael	Chief Executive Officer	Dec 17 '25	Option Exercise	4.55	65,804	299,408	2,570,596	Dec 19 08:00 PM
Castagna Michael	Chief Executive Officer	Dec 17 '25	Sale	6.01	65,804	395,482	2,504,792	Dec 19 08:00 PM
Castagna Michael	Chief Executive Officer	Dec 16 '25	Option Exercise	4.55	21,310	96,960	2,526,102	Dec 16 08:15 PM
Castagna Michael	Chief Executive Officer	Dec 12 '25	Option Exercise	4.55	20,806	94,667	2,525,598	Dec 16 08:15 PM
Castagna Michael	Chief Executive Officer	Dec 16 '25	Sale	6.00	21,310	127,860	2,504,792	Dec 16 08:15 PM
Castagna Michael	Chief Executive Officer	Dec 12 '25	Sale	6.00	20,806	124,836	2,504,792	Dec 16 08:15 PM
MICHAEL CASTAGNA	Director	Dec 12 '25	Proposed Sale	5.81	107,920	627,015		Dec 12 04:26 PM
Castagna Michael	Chief Executive Officer	Dec 02 '25	Option Exercise	4.55	107,920	491,036	2,612,712	Dec 04 07:32 PM
Castagna Michael	Chief Executive Officer	Dec 02 '25	Sale	5.57	107,920	601,114	2,504,792	Dec 04 07:32 PM
Thomson David	EVP Genl Counsel & Secretary	Dec 02 '25	Option Exercise	4.58	147,780	676,788	989,499	Dec 04 07:27 PM
Thomson David	EVP Genl Counsel & Secretary	Dec 02 '25	Sale	5.57	147,780	823,135	841,719	Dec 04 07:27 PM
DAVID THOMSON	Officer	Dec 02 '25	Proposed Sale	5.43	147,780	802,445		Dec 02 04:24 PM
MICHAEL CASTAGNA	Director	Dec 02 '25	Proposed Sale	5.43	107,920	586,006		Dec 02 04:23 PM
Singh Sanjay R	EVP Technical Operations	Nov 14 '25	Sale	5.03	18,777	94,448	455,211	Nov 14 08:00 PM
SANJAY SINGH	Officer	Nov 14 '25	Proposed Sale	5.03	18,777	94,493		Nov 14 04:02 PM
Tross Stuart A	Chief People & Workpl Officer	Sep 16 '25	Sale	5.34	47,000	250,980	1,032,013	Sep 17 07:39 PM
STUART A TROSS	Officer	Sep 16 '25	Proposed Sale	5.34	47,000	250,792		Sep 16 04:05 PM
Binder Steven B.	Director	Jul 16 '25	Sale	3.94	75,367	296,946	830,508	Jul 17 08:51 PM
Thomson David	EVP Genl Counsel & Secretary	Jul 16 '25	Sale	3.94	7,466	29,416	841,719	Jul 17 08:46 PM
DAVID THOMSON	Officer	Jul 16 '25	Proposed Sale	3.94	7,466	29,427		Jul 16 04:10 PM
STEVEN B BINDER	Director	Jul 16 '25	Proposed Sale	3.94	75,367	296,645		Jul 16 04:04 PM
Binder Steven B.	Director	Jun 10 '25	Sale	4.00	64,085	256,340	925,258	Jun 10 08:07 PM
STEVEN B BINDER	Director	Jun 10 '25	Proposed Sale	4.00	64,085	256,430		Jun 10 04:02 PM
Binder Steven B.	Director	May 20 '25	Sale	4.40	12,078	53,143	989,343	May 20 09:45 PM
Thomson David	EVP Genl Counsel & Secretary	May 20 '25	Sale	4.41	2,345	10,341	879,546	May 20 09:44 PM
DAVID THOMSON	Officer	May 20 '25	Proposed Sale	4.41	2,345	10,334		May 20 04:14 PM
STEVEN B BINDER	Director	May 20 '25	Proposed Sale	4.40	12,078	53,184		May 20 04:03 PM
Thomson David	EVP Genl Counsel & Secretary	May 13 '25	Sale	4.68	32,179	150,598	772,427	May 15 09:37 PM
Binder Steven B.	Director	May 13 '25	Sale	4.69	80,144	375,875	1,006,611	May 15 09:35 PM
STEVEN B BINDER	Director	May 13 '25	Proposed Sale	4.69	80,144	375,499		May 13 04:03 PM
DAVID THOMSON	Officer	May 13 '25	Proposed Sale	4.68	32,179	150,717		May 13 04:02 PM

Open in Screener

PAGP

Plains GP Holdings LP

Feb 17 • 04:00PM ET

21.82

+0.23 1.07 %

Energy • Oil & Gas Midstream • USA • NASD

PAGP Plains GP Holdings LP daily Stock Chart

Peers: ET MPLX EPD ENB OKE WMB KMI PPL TRP AM

| Held by: EMLP MLPX SURI UMI ATMP TNGY VDE EIPI ENFR SMIG

Index	-	P/E	17.52	EPS (ttm)	1.25	Insider Own	2.77%	Shs Outstand	197.89M	Perf Week	5.46%
Market Cap	16.62B	Forward P/E	10.98	EPS next Y	1.99	Insider Trans	0.00%	Shs Float	192.41M	Perf Month	8.18%
Enterprise Value	37.63B	PEG	0.74	EPS next Q	0.48	Inst Own	75.89%	Short Float	5.98%	Perf Quarter	24.61%
Income	259.00M	P/S	0.37	EPS this Y	39.03%	Inst Trans	1.68%	Short Ratio	6.65	Perf Half Y	15.88%
Sales	44.86B	P/B	3.21	EPS next Y	9.93%	ROA	0.39%	Short Interest	11.50M	Perf YTD	14.00%
Book/sh	6.80	P/C	14.08	EPS next 5Y	14.88%	ROE	8.61%	52W High	21.97 -0.68%	Perf Year	3.41%
Cash/sh	1.55	P/FCF	7.52	EPS past 3/5Y	8.82% -	ROIC	2.43%	52W Low	16.60 31.41%	Perf 3Y	62.84%
Dividend Est.	1.72 (7.87%)	EV/EBITDA	14.45	Sales past 3/5Y	-8.17% 13.41%	Gross Margin	4.42%	Volatility	1.70% 1.92%	Perf 5Y	148.80%
Dividend TTM	1.56 (7.14%)	EV/Sales	0.84	EPS Y/Y TTM	150.21%	Oper. Margin	3.61%	ATR (14)	0.39	Perf 10Y	21.43%
Dividend Ex-Date	Jan 30, 2026	Quick Ratio	1.01	Sales Y/Y TTM	-10.81%	Profit Margin	0.58%	RSI (14)	74.44	Recom	2.67
Dividend Gr. 3/5Y	22.35% 11.05%	Current Ratio	0.96	EPS Q/Q	661.11%	SMA20	4.77%	Beta	0.53	Target Price	21.00
Payout	136.21%	Debt/Eq	6.93	Sales Q/Q	-15.00%	SMA50	9.95%	Rel Volume	1.21	Prev Close	21.59
Employees	4200	LT Debt/Eq	6.93	Earnings	Feb 06 BMO	SMA200	15.84%	Avg Volume	1.73M	Price	21.82
IPO	Oct 16, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-37.12% -18.87%	Trades		Volume	2,093,983	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Downgrade	BofA Securities	Neutral → Underperform	$19
Jul-25-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-10-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$22
Dec-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$22 → $20
Oct-25-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$22 → $19
Apr-08-24	Resumed	Scotiabank	Sector Outperform	$23
Oct-06-23	Resumed	Goldman	Sell	$13.50
Sep-25-23	Downgrade	Barclays	Equal Weight → Underweight	$15
Sep-06-23	Downgrade	Citigroup	Buy → Neutral	$14 → $15.50
Apr-21-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $17
Dec-09-22	Initiated	Citigroup	Buy	$14
Nov-21-22	Downgrade	JP Morgan	Overweight → Neutral	$15 → $14
Aug-15-22	Upgrade	Stifel	Hold → Buy	$16
Aug-01-22	Upgrade	Seaport Research Partners	Neutral → Buy	$13
Jul-19-22	Upgrade	BofA Securities	Underperform → Neutral	$12
May-12-22	Upgrade	Credit Suisse	Neutral → Outperform	$13 → $14
May-02-22	Resumed	Truist	Buy	$13
Jan-25-22	Upgrade	Bernstein	Mkt Perform → Outperform	$14.50
Jan-10-22	Upgrade	Wolfe Research	Peer Perform → Outperform
Nov-29-21	Resumed	Barclays	Equal Weight

Show Previous Ratings

Feb-06-26 04:02PM	Plains GP Holdings LP (PAGP) Q4 2025 Earnings Call Highlights: Strong EBITDA Performance and ... (GuruFocus.com)
07:51AM	Plains GP: Q4 Earnings Snapshot (Associated Press Finance)
Feb-04-26 07:48AM	Plains GP Gears Up to Report Q4 Earnings: What's in the Cards? (Zacks)
Jan-23-26 03:08AM	Zacks.com featured highlights include Industrial Logistics Properties, Plains GP, ASGN, California Water Service and Dollar Tree (Zacks)
Jan-22-26 09:25AM	Tap These 5 Bargain Stocks With Attractive EV-to-EBITDA Ratios (Zacks)
03:12AM	Loading…
Jan-20-26 03:12AM	Zacks.com featured highlights include Centerra Gold, Plains GP, Angi and Skillsoft (Zacks)
Jan-19-26 07:01AM	4 Value Stocks to Buy Now Amid Trump-Led Market Uncertainty (Zacks)
Jan-16-26 09:40AM	Are Investors Undervaluing Plains Group (PAGP) Right Now? (Zacks)
Jan-08-26 09:33AM	Zacks.com featured highlights include Plains GP, DNOW, Gibraltar Industries, Miller Industries and Sally Beauty (Zacks)
Jan-07-26 08:21AM	5 Value Stocks With Alluring EV-to-EBITDA Ratios to Own Now (Zacks)
Dec-30-25 09:58AM	Seeking Income Into 2026? 3 High-Yield Stocks to Buy Now (Zacks)
Dec-18-25 09:45AM	Ovintiv Stock Drops Nearly 1% in a Month: Time to Hold or Sell? (Zacks)
Dec-15-25 09:40AM	Are Investors Undervaluing Plains Group (PAGP) Right Now? (Zacks)
Dec-10-25 09:48AM	Shell Eyes LLOG Deal to Strengthen Its Gulf of America Portfolio (Zacks)
Dec-09-25 08:26AM	TechnipFMC Wins Major Contract for Ithaca's Captain Field Upgrade (Zacks)
05:34AM	Loading…
Dec-05-25 05:34AM	Zacks.com featured highlights include Plains GP, Edison International, TD SYNNEX, CONMED and PG&E (Zacks)
Dec-04-25 08:09AM	5 Value Stocks With Exciting EV-to-EBITDA Ratios to Scoop Up (Zacks)
Nov-28-25 03:49AM	Best Value Stocks to Buy for Nov. 28 (Zacks)
03:36AM	Best Income Stocks to Buy for Nov. 28 (Zacks)
Nov-27-25 09:40AM	Is Plains Group (PAGP) Stock Undervalued Right Now? (Zacks)
Nov-11-25 09:40AM	Should Value Investors Buy Plains Group (PAGP) Stock? (Zacks)
Nov-06-25 12:02PM	Plains GP Holdings LP (PAGP) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Nov-05-25 07:42AM	Plains GP: Q3 Earnings Snapshot (Associated Press Finance)
Nov-04-25 07:40AM	Earnings To Watch: Plains GP Holdings LP (PAGP) Reports Q3 2025 Result (GuruFocus.com)
Sep-09-25 09:40AM	Are Investors Undervaluing Plains Group (PAGP) Right Now? (Zacks)
Sep-03-25 08:38AM	Diamondback Declares Divestment of Equity Interest in EPIC Crude (Zacks)
06:28AM	This 8.5%-Yielding Dividend Stock's "Epic" Deal Will Give It Even More Fuel to Continue Growing Its Payout (Motley Fool)
Sep-02-25 10:24AM	Pembina Pipeline: Not a Buy Yet, But Still Worth Holding (Zacks)
Aug-28-25 03:47AM	Zacks.com featured highlights Post Holdings, Plains GP, Greenbrier, POSCO and Sally Beauty (Zacks)
Aug-27-25 07:31AM	5 Value Stocks With Exciting EV-to-EBITDA Ratios to Own Now (Zacks)
08:06AM	Loading…
Aug-25-25 08:06AM	Invest in Value With These 5 High Earnings Yield Stocks (Zacks)
Aug-20-25 09:40AM	Is Plains Group (PAGP) Stock Undervalued Right Now? (Zacks)
Aug-19-25 09:40AM	Has Plains Group (PAGP) Outpaced Other Oils-Energy Stocks This Year? (Zacks)
Aug-08-25 07:55AM	Plains GP: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Plains All American Reports Second-Quarter 2025 Results (GlobeNewswire)
Aug-07-25 12:26PM	Plains All American to Post Q2 Earnings: What's in the Offing? (Zacks)
Aug-06-25 08:39AM	Power Up Your Portfolio Value With These 5 High Earnings Yield Stocks (Zacks)
Aug-05-25 01:23PM	Energy Transfer to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-04-25 12:54PM	Occidental Set to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
12:11PM	Devon Energy to Report Q2 Earnings: How Should You Play the Stock? (Zacks)
09:40AM	Should Value Investors Buy Plains Group (PAGP) Stock? (Zacks)
08:40AM	Petrobras to Report Q2 Earnings: What's in the Offing for the Stock? (Zacks)
08:06AM	Canadian Natural to Report Q2 Earnings: What's in the Offing? (Zacks)
08:04AM	Cheniere Energy to Report Q2 Earnings: What's in the Offing? (Zacks)
08:03AM	APA Corporation Q2 Earnings on Deck: Here's How It Will Fare (Zacks)
Jul-29-25 09:40AM	Is Enbridge (ENB) Stock Outpacing Its Oils-Energy Peers This Year? (Zacks)
Jul-28-25 08:42AM	Zacks.com featured highlights include AZZ, Plains GP, DMC Global, MRC Global and The Greenbrier Companies (Zacks)
Jul-25-25 07:07AM	5 Value Stocks With Exciting EV-to-EBITDA Ratios to Snap Up Now (Zacks)
Jul-22-25 08:53AM	5 High Earnings Yield Stocks to Tap Into Value Investing Gains (Zacks)
Jul-18-25 09:40AM	Should Value Investors Buy Plains Group (PAGP) Stock? (Zacks)
Jul-03-25 10:42AM	Why Plains All American Pipeline Jumped Nearly 11% in June (Motley Fool)
Jul-02-25 05:00PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of Second Quarter 2025 Earnings (GlobeNewswire)
Jun-25-25 03:00AM	Zacks.com featured highlights Affiliated Managers, Koninklijke Ahold Delhaize, Noah, Plains GP and Gibraltar Industries (Zacks)
Jun-24-25 09:40AM	Are Investors Undervaluing Plains Group (PAGP) Right Now? (Zacks)
07:26AM	5 Value Stocks With Impressive EV-to-EBITDA Ratios to Own Now (Zacks)
Jun-19-25 10:26AM	A $3.8 Billion Deal Is Making These Ultra-High-Yielding Dividend Stocks Even Safer (Motley Fool)
Jun-18-25 05:55PM	Why Plains All American Pipeline Stock Was a Winner on Wednesday (Motley Fool)
12:11PM	Plains All American to Sell Canadian NGL Business to Keyera for $3.75B (Zacks)
Jun-17-25 04:15PM	Plains All American Executes Definitive Agreements for $3.75 Billion Sale of NGL Business to Keyera (GlobeNewswire)
May-24-25 09:46AM	If You Like Energy Transfer's 7.4%-Yielding Payout, You Should Check Out This 9.1%-Yielding Dividend Stock (Motley Fool)
May-10-25 03:07AM	Plains GP Holdings LP (PAGP) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and ... (GuruFocus.com)
May-09-25 07:50AM	Plains GP: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Plains All American Reports First-Quarter 2025 Results (GlobeNewswire)
May-08-25 09:24AM	Plains GP Holdings LP (PAGP) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Apr-30-25 08:30AM	My Favorite Place To Buy Passive Income Today (Seeking Alpha)
Apr-29-25 09:44PM	Is Plains GP Holdings, L.P. (PAGP) a Small-Cap Energy Stock Hedge Funds Are Buying? (Insider Monkey)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-23-25 11:28AM	How To Build A $100,000 Dividend Snowball In April 2025 (Seeking Alpha)
08:00AM	U.S. LNG Dealmaking Picks Up With Benefits For Midstream (Seeking Alpha)
Apr-20-25 11:01PM	Plains GP Holdings Is A Buy With Its Massive FCF (Seeking Alpha)
Apr-16-25 08:00AM	Midstream/MLPs 2024 Leverage Ratios On Target (Seeking Alpha)
Apr-15-25 08:00AM	Midstream/MLP Dividends Steady As Markets Swing (Seeking Alpha)
Apr-11-25 09:15AM	NXG: 16% Yield On Infrastructure, Tax Deferral Benefit (Seeking Alpha)
Apr-02-25 04:30PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of First Quarter 2025 Earnings (GlobeNewswire)
05:48AM	Plains All American: Undervalued, Reliable Midstream Operator (Seeking Alpha)
Mar-26-25 04:30PM	Plains Announces Retirement of President Harry Pefanis and Assignment Updates to Board of Directors (GlobeNewswire)
Mar-04-25 09:40AM	Is Plains Group (PAGP) Stock Undervalued Right Now? (Zacks)
Feb-14-25 09:40AM	Should Value Investors Buy Plains Group (PAGP) Stock? (Zacks)
Feb-08-25 02:09AM	Plains GP Holdings LP (PAGP) Q4 2024 Earnings Call Highlights: Strong Performance and Strategic ... (GuruFocus.com)
Feb-07-25 07:25AM	Plains GP: Q4 Earnings Snapshot (Associated Press Finance)
07:03AM	Plains All American Reports Fourth-Quarter and Full-Year 2024 Results; Provides Update on Efficient Growth Initiatives and Announces 2025 Guidance (GlobeNewswire)
Feb-06-25 07:10AM	Plains GP Holdings LP (PAGP) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-03-25 02:03PM	Why Plains GP Holdings (PAGP) is Skyrocketing So Far In 2025? (Insider Monkey)
Jan-30-25 08:50AM	Plains GP (PAGP) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Jan-29-25 09:40AM	Are Investors Undervaluing Plains Group (PAGP) Right Now? (Zacks)
Jan-13-25 09:40AM	Is Plains Group (PAGP) Stock Undervalued Right Now? (Zacks)
08:50AM	Fast-paced Momentum Stock Plains GP (PAGP) Is Still Trading at a Bargain (Zacks)
Jan-09-25 10:01AM	Strength Seen in Plains GP (PAGP): Can Its 6.1% Jump Turn into More Strength? (Zacks)
Jan-07-25 07:21PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of Fourth Quarter 2024 Earnings (GlobeNewswire) +6.12%
07:18PM	Plains All American Announces Bolt-on Acquisitions, Capital Structure Optimization and Distribution Increase (GlobeNewswire)
07:18PM	Plains All American Announces Bolt-on Acquisitions, Capital Structure Optimization & Distribution Increase (GlobeNewswire)
Dec-05-24 04:40PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
Nov-11-24 12:55PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)
Nov-09-24 02:08AM	Plains GP Holdings LP (PAGP) Q3 2024 Earnings Call Highlights: Strong Operational Performance ... (GuruFocus.com)
Nov-08-24 07:53AM	Plains GP: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Plains All American Reports Third-Quarter 2024 Results (GlobeNewswire)
Nov-07-24 07:03AM	Plains GP Holdings LP (PAGP) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Oct-08-24 09:40AM	Should Value Investors Buy Plains Group (PAGP) Stock? (Zacks)
Oct-02-24 04:30PM	Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of Third Quarter 2024 Earnings (GlobeNewswire)
Sep-11-24 11:13PM	Analyst Report: Plains GP Holdings, L.P. (Morningstar Research)

Plains GP Holdings LP owns and operates midstream energy infrastructure and provides logistics services primarily for crude oil, natural gas liquids and natural gas through its indirect investment in Plains All American Pipeline, L.P. The firm operates through the following segments: Transportation, Facilities and Supply and Logistics. The Transportation segment consists of fee-based activities associated with transporting crude oil and NGL on pipelines, gathering systems, trucks and barges. The Facilities segment consists of fee-based activities associated with providing storage, terminalling and throughput services primarily for crude oil, NGL and natural gas, as well as NGL fractionation and isomerization services and natural gas and condensate processing services. The Supply and Logistics segment consists of storage of inventory during contango market conditions and the seasonal storage of NGL, purchase of NGL from producers, refiners, processors and other marketers, extraction of NGL from gas processed at the facilities. The company was founded in July 2013 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Ziemba Lawrence Michael	Director	Aug 14 '25	Option Exercise	19,550	87,780	Aug 18 05:05 PM
SHACKOULS BOBBY S	Director	Aug 14 '25	Option Exercise	19,550	73,401	Aug 18 05:03 PM
RAYMOND JOHN T	Director	Aug 14 '25	Option Exercise	19,550	315,394	Aug 18 05:01 PM
Pruner Alexandra	Director	Aug 14 '25	Option Exercise	19,550	80,894	Aug 18 05:00 PM
PETERSEN GARY R	Director	Aug 14 '25	Option Exercise	19,550	68,144	Aug 18 04:54 PM
McCarthy Kevin S	Director	Aug 14 '25	Option Exercise	19,550	148,691	Aug 18 04:52 PM
DeSanctis Ellen	Director	Aug 14 '25	Option Exercise	7,650	37,100	Aug 18 04:50 PM
Burk Victor	Director	Aug 14 '25	Option Exercise	19,550	42,923	Aug 18 04:47 PM

AGIO

Agios Pharmaceuticals Inc

MNKD

Mannkind Corp

PAGP

Plains GP Holdings LP

Upgrade your FINVIZ experience